Melanoma drug combo improves patient survival rate, decreases risk of harsh side effect
A UCLA researcher at the Jonsson Comprehensive Cancer Center helped pioneer a new therapy that combines the drug Zelboraf® with an experimental drug cobimetinib, allowing metastatic melanoma...